Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Allarity Therapeutics Inc (ALLR)

Allarity Therapeutics Inc (ALLR)
0.9700 x 6 1.0000 x 1
Post-market by (Cboe BZX)
0.9900 -0.0400 (-3.88%) 04/22/25 [NASDAQ]
0.9700 x 6 1.0000 x 1
Post-market 0.9900 unch (unch) 17:45 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9500
Day High
1.0300
Open 1.0300
Previous Close 1.0300 1.0300
Volume 747,580 747,580
Avg Vol 1,597,179 1,597,179
Stochastic %K 85.39% 85.39%
Weighted Alpha -92.33 -92.33
5-Day Change +0.2739 (+38.20%) +0.2739 (+38.20%)
52-Week Range 0.6138 - 103.8000 0.6138 - 103.8000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,525
  • Shares Outstanding, K 17,015
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,520 K
  • EBIT $ -18 M
  • EBITDA $ -8 M
  • 60-Month Beta -0.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.58
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -675.88
  • Most Recent Earnings $-7.71 on 11/14/24
  • Next Earnings Date 05/13/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -664.86
  • Growth Rate Est. (year over year) +250.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6138 +61.44%
on 04/09/25
Period Open: 0.9900
1.2300 -19.44%
on 03/26/25
+0.0009 (+0.09%)
since 03/21/25
3-Month
0.6138 +61.44%
on 04/09/25
Period Open: 1.0100
1.9900 -50.21%
on 01/27/25
-0.0191 (-1.89%)
since 01/22/25
52-Week
0.6138 +61.44%
on 04/09/25
Period Open: 42.6000
103.8000 -99.05%
on 05/02/24
-41.6091 (-97.67%)
since 04/22/24

Most Recent Stories

More News
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...

CVS : 65.45 (+0.43%)
EXAS : 44.15 (+2.44%)
ABBV : 173.78 (+2.13%)
RSLS : 0.3946 (+2.97%)
ALLR : 0.9909 (-3.80%)
Allarity Therapeutics Reports Extended Treatment Duration and Financial Strength to Advance Stenoparib for Ovarian Cancer

Allarity Therapeutics reports positive Phase 2 trial results for stenoparib in ovarian cancer and expands laboratory services.Quiver AI SummaryAllarity Therapeutics has reported significant progress in...

ALLR : 0.9909 (-3.80%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR). Such...

ALLR : 0.9909 (-3.80%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR). Such...

ALLR : 0.9909 (-3.80%)
Allarity Therapeutics (NASDAQ: ALLR) Reports Early Success in Phase 2 Trial for Breast Cancer Drug IXEMPRA®

Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage pharmaceutical company, recently announced preliminary results from its Phase 2 clinical trial assessing the

ALLR : 0.9909 (-3.80%)
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

New strategy aligns with ongoing shift in oncology standard-of-caretowards combination therapies Combination therapy focus expected to improve the...

ALLR : 0.9909 (-3.80%)
Allarity Therapeutics Announces Executive Leadership Transition

  Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,Joan Y. Brown, CPA, to Interim Chief Financial Officer Press release      ...

ALLR : 0.9909 (-3.80%)
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.

Cambridge, MA U.S.A. (June 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...

ALLR : 0.9909 (-3.80%)
Allarity Therapeutics Reports First Quarter 2022 Financial Results

Cambridge, MA U.S.A. (May 27, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...

ALLR : 0.9909 (-3.80%)
Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Cambridge, MA U.S.A. (May 18, 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity...

ALLR : 0.9909 (-3.80%)

Business Summary

Allarity Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel oncology therapeutics together with drug-specific DRP(R) companion diagnostics for personalized cancer care. Allarity Therapeutics Inc. is based in Cambridge, MA U.S.A.

See More

Key Turning Points

3rd Resistance Point 1.1105
2nd Resistance Point 1.0702
1st Resistance Point 1.0306
Last Price 0.9909
1st Support Level 0.9507
2nd Support Level 0.9104
3rd Support Level 0.8708

See More

52-Week High 103.8000
Fibonacci 61.8% 64.3829
Fibonacci 50% 52.2069
Fibonacci 38.2% 40.0309
Last Price 0.9909
52-Week Low 0.6138

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro